TLR4 and metabolic dysfunction-associated steatohepatitis: In our current study, the prevention of the expression of hepatic TLR4, NF-κB, TGF-β by rifaximin highlights its suppressive effect on the TLR4/NF-κB signaling pathway in NASH rat model (Figure 5b–d).